Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2024
|
Cedric Francois Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
182,146
-27.84%
|
-
|
|
Sep 27
2024
|
David O. Watson General Counsel |
BUY
Bona fide gift
|
Direct |
10,569
+8.24%
|
-
|
|
Sep 27
2024
|
David O. Watson General Counsel |
SELL
Bona fide gift
|
Indirect |
10,569
-13.1%
|
-
|
|
Sep 23
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+2.94%
|
$59,800
$13.19 P/Share
|
|
Sep 16
2024
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
37,000
-14.26%
|
$1,332,000
$36.44 P/Share
|
|
Sep 16
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
192
-0.5%
|
$6,912
$36.21 P/Share
|
|
Sep 03
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
550
-1.41%
|
$21,450
$39.49 P/Share
|
|
Aug 12
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,201
+7.93%
|
$67,613
$13.85 P/Share
|
|
Jun 28
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+0.67%
|
$11,700
$13.19 P/Share
|
|
Jun 21
2024
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
37,000
-10.76%
|
$1,443,000
$39.43 P/Share
|
|
May 20
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,500
+2.1%
|
$73,500
$3.76 P/Share
|
|
May 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
78,907
-2.23%
|
$3,393,001
$43.01 P/Share
|
|
May 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
78,907
+6.19%
|
$315,628
$4.31 P/Share
|
|
Apr 18
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
14,164
+16.75%
|
-
|
|
Apr 18
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
14,164
-15.18%
|
-
|
|
Apr 12
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+1.11%
|
$19,500
$13.19 P/Share
|
|
Apr 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
69,107
-2.93%
|
$3,731,778
$54.52 P/Share
|
|
Apr 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,107
+5.51%
|
$207,321
$3.76 P/Share
|
|
Apr 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,000
-4.11%
|
$232,000
$58.66 P/Share
|
|
Apr 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+3.95%
|
$40,000
$10.03 P/Share
|
|
Mar 19
2024
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
18,681
-9.7%
|
$1,064,817
$57.18 P/Share
|
|
Mar 18
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
9,913
-15.34%
|
$555,128
$56.9 P/Share
|
|
Mar 15
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
184
-0.47%
|
$10,304
$56.46 P/Share
|
|
Mar 13
2024
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
11,220
-8.64%
|
$639,540
$57.72 P/Share
|
|
Mar 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
69,107
-1.97%
|
$4,284,634
$62.64 P/Share
|
|
Mar 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,107
+5.51%
|
$207,321
$3.67 P/Share
|
|
Mar 06
2024
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,762
+3.39%
|
$48,906
$13.85 P/Share
|
|
Mar 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-3.06%
|
$378,000
$63.41 P/Share
|
|
Mar 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+5.7%
|
$60,000
$10.03 P/Share
|
|
Mar 01
2024
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
250,000
-10.56%
|
$16,000,000
$64.01 P/Share
|
|
Mar 01
2024
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+19.14%
|
$1,000,000
$4.04 P/Share
|
|
Feb 12
2024
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
781
-0.75%
|
$52,327
$67.77 P/Share
|
|
Feb 12
2024
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,148
-1.23%
|
$76,916
$67.77 P/Share
|
|
Feb 12
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,431
-1.51%
|
$95,877
$67.77 P/Share
|
|
Feb 12
2024
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,962
-1.25%
|
$265,454
$67.77 P/Share
|
|
Feb 12
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,148
-0.1%
|
$76,916
$67.77 P/Share
|
|
Feb 12
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
597
-0.92%
|
$39,999
$67.77 P/Share
|
|
Jan 30
2024
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
883
-1.87%
|
$57,395
$65.53 P/Share
|
|
Jan 30
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
971
-1.67%
|
$63,115
$65.53 P/Share
|
|
Jan 29
2024
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
906
-0.96%
|
$57,984
$64.14 P/Share
|
|
Jan 29
2024
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
906
-0.86%
|
$57,984
$64.14 P/Share
|
|
Jan 29
2024
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
835
-1.22%
|
$53,440
$64.14 P/Share
|
|
Jan 29
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
906
-0.95%
|
$57,984
$64.14 P/Share
|
|
Jan 29
2024
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,843
-0.89%
|
$181,952
$64.14 P/Share
|
|
Jan 29
2024
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
367
-0.77%
|
$23,488
$64.14 P/Share
|
|
Jan 29
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
874
-0.08%
|
$55,936
$64.14 P/Share
|
|
Jan 29
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
279
-0.48%
|
$17,856
$64.14 P/Share
|
|
Jan 29
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
367
-0.56%
|
$23,488
$64.14 P/Share
|
|
Jan 23
2024
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
4,286
-8.25%
|
$270,018
$63.69 P/Share
|
|
Jan 23
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,378
-11.21%
|
$464,814
$63.69 P/Share
|